Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy

Raffaele Coppini, Luca Mazzoni, Cecilia Ferrantini, Francesca Gentile, Josè Manuel Pioner, Tina Laurino, Lorenzo Santini, Valentina Bargelli, Matteo Rotellini, Gianluca Bartolucci, Claudia Crocini, Leonardo Sacconi, Chiara Tesi, Luiz Belardinelli, Jil Tardiff, Alessandro Mugelli, Iacopo Olivotto, Elisabetta Cerbai, Corrado Poggesi

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

Background - Current therapies are ineffective in preventing the development of cardiac phenotype in young carriers of mutations associated with hypertrophic cardiomyopathy (HCM). Ranolazine, a late Na+ current blocker, reduced the electromechanical dysfunction of human HCM myocardium in vitro. Methods and Results - To test whether long-term treatment prevents cardiomyopathy in vivo, transgenic mice harboring the R92Q troponin-T mutation and wild-type littermates received an oral lifelong treatment with ranolazine and were compared with age-matched vehicle-treated animals. In 12-months-old male R92Q mice, ranolazine at therapeutic plasma concentrations prevented the development of HCM-related cardiac phenotype, including thickening of the interventricular septum, left ventricular volume reduction, left ventricular hypercontractility, diastolic dysfunction, left-atrial enlargement and left ventricular fibrosis, as evaluated in vivo using echocardiography and magnetic resonance. Left ventricular cardiomyocytes from vehicle-treated R92Q mice showed marked excitation-contraction coupling abnormalities, including increased diastolic [Ca2+] and Ca2+ waves, whereas cells from treated mutants were undistinguishable from those from wild-type mice. Intact trabeculae from vehicle-treated mutants displayed inotropic insufficiency, increased diastolic tension, and premature contractions; ranolazine treatment counteracted the development of myocardial mechanical abnormalities. In mutant myocytes, ranolazine inhibited the enhanced late Na+ current and reduced intracellular [Na+] and diastolic [Ca2+], ultimately preventing the pathological increase of calmodulin kinase activity in treated mice. Conclusions - Owing to the sustained reduction of intracellular Ca2+ and calmodulin kinase activity, ranolazine prevented the development of morphological and functional cardiac phenotype in mice carrying a clinically relevant HCM-related mutation. Pharmacological inhibitors of late Na+ current are promising candidates for an early preventive therapy in young phenotype-negative subjects carrying high-risk HCM-related mutations.

Original languageEnglish (US)
Article numbere003565
JournalCirculation: Heart Failure
Volume10
Issue number3
DOIs
StatePublished - Mar 1 2017

Keywords

  • arrhythmias
  • calcium
  • cardiomyocyte
  • drug therapy
  • prevention
  • remodeling
  • sodium

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy'. Together they form a unique fingerprint.

  • Cite this

    Coppini, R., Mazzoni, L., Ferrantini, C., Gentile, F., Pioner, J. M., Laurino, T., Santini, L., Bargelli, V., Rotellini, M., Bartolucci, G., Crocini, C., Sacconi, L., Tesi, C., Belardinelli, L., Tardiff, J., Mugelli, A., Olivotto, I., Cerbai, E., & Poggesi, C. (2017). Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy. Circulation: Heart Failure, 10(3), [e003565]. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003565